Nexalin Technology Advances Addiction Treatment With New Patent
Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW), a pioneering company in the field of Deep Intracranial Frequency Stimulation (DIFS™), has recently received a pivotal patent from the United States Patent and Trademark Office. This patent, titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD)," marks a significant milestone for the company.
Nexalin's Breakthrough Technology
The DIFS™ technology represents a groundbreaking approach to combat substance use disorders, including opioid dependency and alcohol use disorder. By leveraging non-invasive methodologies, DIFS™ aims to help individuals navigate through the challenges of addiction treatment without the reliance on drugs or invasive procedures.
With DIFS™, the potential exists to modify neural pathways that are deeply rooted in addiction behaviors. As the technology engages the brain's dynamics through specific frequencies, it could regulate withdrawal symptoms and provide support for those seeking recovery.
Leadership Insights on New Developments
Mark White, CEO of Nexalin Technology, expressed enthusiasm regarding the patent's implications: “This milestone reaffirms our commitment to innovative treatment approaches for substance use disorders, which continue to plague public health globally,” he noted. He highlighted that the DIFS™ technology aims not only to treat addiction but also the underlying psychological conditions such as anxiety and depression that often accompany substance use disorders.
The management’s vision is clear; by targeting core symptoms through neuromodulation, Nexalin's technology hopes to pave the way for safer and more effective treatment modalities.
The Need for Innovative Solutions
The substance use disorder crisis remains a pressing issue, with millions of individuals affected worldwide. Current treatments often involve medication-assisted therapies that can create dependency itself, leaving many in search of alternatives that do not carry such risks.
Nexalin’s DIFS™ offers an innovative solution to this dilemma, focusing on minimizing withdrawal symptoms while enhancing long-term recovery without the side effects associated with conventional therapeutic approaches.
Pioneering the Future of Treatment
David Owens, CMO of Nexalin Technology, anticipates an impactful shift in addiction treatment following the patent approval. He commented, “This recognition by the USPTO solidifies our innovative approach and the necessity for new treatment options in the addiction landscape.” He reinforced the company's commitment to addressing urgent medical needs and redefining addiction care through non-invasive technology.
Expanding Intellectual Property Portfolio
This new patent adds to Nexalin's growing array of intellectual property, demonstrating the company’s ongoing dedication to exploring the potential of non-invasive neuromodulation technologies. As Nexalin continues to evolve and enhance its product offerings, it aims to provide advanced solutions that improve the care and recovery processes for mental health and addiction issues.
Looking Forward with Nexalin
Nexalin remains focused on its mission to reshape the standards of treatment in addiction and mental health fields. With technologies that are already approved in markets like China and Brazil, the company is poised for future expansions and innovations that promise to enhance patient outcomes.
Frequently Asked Questions
What is DIFS™ technology?
DIFS™ technology is a non-invasive method developed by Nexalin to aid in the treatment of substance use disorders, utilizing dynamic frequencies to potentially alter neural pathways associated with addiction.
Why is the recent patent important?
The patent validates the innovative nature of DIFS™ technology and supports Nexalin's ongoing commitment to provide effective non-invasive treatment alternatives for individuals with substance use disorders.
What conditions can DIFS™ technology address?
DIFS™ technology is designed to help individuals struggling with opioid use disorder, alcohol use disorder, and stimulant addiction, by regulating withdrawal symptoms and mitigating cravings.
How does Nexalin's technology differ from traditional methods?
Nexalin's approach focuses on non-invasive solutions that aim to reduce reliance on medications or other invasive treatments, addressing both addiction and its psychological underpinnings without significant side effects.
Where can I learn more about Nexalin Technology?
For comprehensive information on Nexalin Technology and its innovative solutions, you can visit www.nexalin-usa.com.
